As of June 12, 2025, Onxeo SA has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $0.21, this represents a potential upside of -1827.5%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -1916.4% |
| Potential Upside (10-year) | -1827.5% |
| Discount Rate (WACC) | 5.9% - 7.6% |
Revenue is projected to grow from $1 million in 12-2022 to $2 million by 12-2032, representing a compound annual growth rate of approximately 7.2%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2022 | 1 | 64% |
| 12-2023 | 2 | 5% |
| 12-2024 | 2 | 2% |
| 12-2025 | 2 | 5% |
| 12-2026 | 2 | 2% |
| 12-2027 | 2 | 4% |
| 12-2028 | 2 | 2% |
| 12-2029 | 2 | 3% |
| 12-2030 | 2 | 2% |
| 12-2031 | 2 | 4% |
| 12-2032 | 2 | 2% |
Net profit margin is expected to improve from -1356% in 12-2022 to -1304% by 12-2032, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2022 | (20) | -1356% |
| 12-2023 | (20) | -1311% |
| 12-2024 | (20) | -1310% |
| 12-2025 | (21) | -1308% |
| 12-2026 | (22) | -1306% |
| 12-2027 | (23) | -1305% |
| 12-2028 | (23) | -1305% |
| 12-2029 | (24) | -1304% |
| 12-2030 | (24) | -1304% |
| 12-2031 | (25) | -1304% |
| 12-2032 | (26) | -1304% |
. Projected CapEx is expected to maintain at approximately 4% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2023 | 0 |
| 12-2024 | 0 |
| 12-2025 | 0 |
| 12-2026 | 0 |
| 12-2027 | 0 |
| 12-2028 | 0 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 835 |
| Days Inventory | 0 |
| Days Payables | 2,692 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2023 | (18) | (0) | 0 | 2 | (19) |
| 2024 | (18) | (0) | 0 | (0) | (17) |
| 2025 | (19) | (0) | 0 | 0 | (19) |
| 2026 | (19) | (0) | 0 | 0 | (20) |
| 2027 | (20) | (0) | 0 | (0) | (20) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -1916.4% |
| 10-Year DCF (Growth) | 0.00 | -1827.5% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Onxeo SA (ALONX.PA) a buy or a sell? Onxeo SA is definitely a sell. Based on our DCF analysis, Onxeo SA (ALONX.PA) appears to be overvalued with upside potential of -1827.5%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $0.21.